Loading...

SalvaRx Group

BST:N3LN
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
N3LN
BST
£4M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

SalvaRx Group plc discovers and develops immune-oncology drugs. The last earnings update was 210 days ago. More info.


Add to Portfolio Compare Print
  • SalvaRx Group has significant price volatility in the past 3 months.
N3LN Share Price and Events
7 Day Returns
-6.4%
BST:N3LN
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-64.6%
BST:N3LN
-5.6%
DE Biotechs
-4.5%
DE Market
N3LN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
SalvaRx Group (N3LN) -6.4% 19.1% -49.6% -64.6% -82.4% -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • N3LN underperformed the Biotechs industry which returned -5.6% over the past year.
  • N3LN underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
N3LN
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for SalvaRx Group's competitors could be found in our database.

Value

 Is SalvaRx Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether SalvaRx Group is trading at an attractive price based on the cash flow it is expected to produce in the future. But as SalvaRx Group has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for SalvaRx Group. This is due to cash flow or dividend data being unavailable. The share price is €0.0691.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for SalvaRx Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are SalvaRx Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:N3LN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in GBP £-0.07
AIM:SALV Share Price ** AIM (2019-04-25) in GBP £0.11
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of SalvaRx Group.

BST:N3LN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:SALV Share Price ÷ EPS (both in GBP)

= 0.11 ÷ -0.07

-1.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SalvaRx Group is loss making, we can't compare its value to the Europe Biotechs industry average.
  • SalvaRx Group is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does SalvaRx Group's expected growth come at a high price?
Raw Data
BST:N3LN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for SalvaRx Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on SalvaRx Group's assets?
Raw Data
BST:N3LN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in GBP £-0.03
AIM:SALV Share Price * AIM (2019-04-25) in GBP £0.11
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
BST:N3LN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:SALV Share Price ÷ Book Value per Share (both in GBP)

= 0.11 ÷ -0.03

-3.02x

* Primary Listing of SalvaRx Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SalvaRx Group has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through SalvaRx Group's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess SalvaRx Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. SalvaRx Group has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is SalvaRx Group expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SalvaRx Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is SalvaRx Group expected to grow at an attractive rate?
  • Unable to compare SalvaRx Group's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare SalvaRx Group's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare SalvaRx Group's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:N3LN Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:N3LN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:N3LN Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
BST:N3LN Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2018-06-30 -2 -3
2018-03-31 -2 -2
2017-12-31 -2 -2
2017-09-30 -2 -2
2017-06-30 -2 -2
2017-03-31 -2 -2
2016-12-31 -2 -2
2016-09-30 -1 -2
2015-12-31 -1 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if SalvaRx Group is high growth as no earnings estimate data is available.
  • Unable to determine if SalvaRx Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:N3LN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from SalvaRx Group Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:N3LN Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
BST:N3LN Past Financials Data
Date (Data in GBP Millions) EPS *
2018-06-30 -0.07
2018-03-31 -0.06
2017-12-31 -0.05
2017-09-30 -0.05
2017-06-30 -0.05
2017-03-31 -0.05
2016-12-31 -0.06
2016-09-30 -0.05
2015-12-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if SalvaRx Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. SalvaRx Group's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. SalvaRx Group's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess SalvaRx Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
SalvaRx Group has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has SalvaRx Group performed over the past 5 years?

  • SalvaRx Group's last earnings update was 210 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare SalvaRx Group's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • SalvaRx Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare SalvaRx Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare SalvaRx Group's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
SalvaRx Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from SalvaRx Group Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:N3LN Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 -2.55 1.17
2018-03-31 -2.15 1.18
2017-12-31 -1.74 1.19
2017-09-30 -1.80 1.10
2017-06-30 -1.86 1.02
2017-03-31 -1.95 0.86
2016-12-31 -2.04 0.69
2016-09-30 -2.04 -0.06 0.79
2015-12-31 -0.49 0.39
2014-12-31 0.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if SalvaRx Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if SalvaRx Group has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if SalvaRx Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess SalvaRx Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
SalvaRx Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is SalvaRx Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up SalvaRx Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • SalvaRx Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • SalvaRx Group's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of SalvaRx Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • SalvaRx Group has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from SalvaRx Group Company Filings, last reported 9 months ago.

BST:N3LN Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 -0.99 4.23 1.08
2018-03-31 -0.99 4.23 1.08
2017-12-31 0.97 2.79 0.57
2017-09-30 0.97 2.79 0.57
2017-06-30 1.97 2.03 0.91
2017-03-31 1.97 2.03 0.91
2016-12-31 2.43 0.62 0.97
2016-09-30 2.43 0.62 0.97
2015-12-31 1.69 0.00 0.57
2014-12-31 1.29 0.00 1.34
  • SalvaRx Group has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if SalvaRx Group's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • SalvaRx Group has less than a year of cash runway based on current free cash flow.
  • SalvaRx Group has less than a year of cash runway if free cash flow continues to grow at historical rates of 38% each year.
X
Financial health checks
We assess SalvaRx Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. SalvaRx Group has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is SalvaRx Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from SalvaRx Group dividends.
If you bought €2,000 of SalvaRx Group shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate SalvaRx Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate SalvaRx Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:N3LN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:N3LN Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as SalvaRx Group has not reported any payouts.
  • Unable to verify if SalvaRx Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of SalvaRx Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as SalvaRx Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess SalvaRx Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can SalvaRx Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. SalvaRx Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of SalvaRx Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • SalvaRx Group has no CEO, or we have no data on them.
Management Team

Denham Hervey Eke

TITLE
CFO & Director
AGE
66
TENURE
0.3 yrs
Board of Directors

Jim Mellon

TITLE
Non Executive Chairman
AGE
61

Denham Hervey Eke

TITLE
CFO & Director
AGE
66
TENURE
0.3 yrs

Greg Bailey

TITLE
Non Executive Director
AGE
62
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess SalvaRx Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. SalvaRx Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

SalvaRx Group plc discovers and develops immune-oncology drugs. The company is based in Ramsey, Isle of Man.

Details
Name: SalvaRx Group plc
N3LN
Exchange: BST
Founded:
£4,464,568
36,699,642
Website: http://www.salvarx.io
Address: SalvaRx Group plc
Commerce House,
1 Bowring Road,
Ramsey,
IM8 2LQ,
Isle of Man
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM SALV Ordinary Shares London Stock Exchange AIM Market GB GBP 22. Mar 2016
OTCPK SLVA.F Ordinary Shares Pink Sheets LLC US USD 22. Mar 2016
BST N3LN Ordinary Shares Boerse-Stuttgart DE EUR 22. Mar 2016
Number of employees
Current staff
Staff numbers
2
SalvaRx Group employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:12
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2017/06/30
Last earnings filing: 2018/09/27
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.